home / stock / smmt / smmt quote
Last: | $8.685 |
---|---|
Change Percent: | 16.94% |
Open: | $9.07 |
Close: | $8.685 |
High: | $9.5 |
Low: | $7.515 |
Volume: | 34,333,160 |
Last Trade Date Time: | 05/31/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$8.685 | $9.07 | $8.685 | $9.5 | $7.515 | 34,333,160 | 05-31-2024 |
$10.92 | $2.85 | $10.92 | $11.25 | $2.64 | 31,992,340 | 05-30-2024 |
$2.935 | $2.34 | $2.935 | $3.05 | $2.3 | 7,866,746 | 05-29-2024 |
$2.39 | $3.38 | $2.39 | $3.38 | $2.1 | 13,548,499 | 05-28-2024 |
$3.38 | $3.51 | $3.38 | $3.95 | $3.2 | 9,177,875 | 05-27-2024 |
$3.38 | $3.51 | $3.38 | $3.95 | $3.2 | 9,177,875 | 05-24-2024 |
$4.32 | $4.41 | $4.32 | $4.43 | $4.25 | 1,982,758 | 05-23-2024 |
$4.39 | $4.5 | $4.39 | $4.54 | $4.3 | 1,191,776 | 05-22-2024 |
$4.39 | $4.52 | $4.39 | $4.61 | $4.35 | 1,416,219 | 05-21-2024 |
$4.54 | $4.43 | $4.54 | $4.57 | $4.425 | 963,026 | 05-20-2024 |
$4.44 | $4.54 | $4.44 | $4.63 | $4.425 | 1,180,801 | 05-17-2024 |
$4.51 | $4.47 | $4.51 | $4.64 | $4.41 | 1,323,617 | 05-16-2024 |
$4.49 | $4.81 | $4.49 | $4.8899 | $4.41 | 1,836,185 | 05-15-2024 |
$4.685 | $4.88 | $4.685 | $5.12 | $4.68 | 1,666,434 | 05-14-2024 |
$4.8 | $4.6 | $4.8 | $5.08 | $4.51 | 2,065,715 | 05-13-2024 |
$4.65 | $4.77 | $4.65 | $4.99 | $4.6 | 1,781,959 | 05-10-2024 |
$4.78 | $5.01 | $4.78 | $5.1582 | $4.645 | 2,083,819 | 05-09-2024 |
$4.96 | $5.29 | $4.96 | $5.39 | $4.94 | 2,711,432 | 05-08-2024 |
$5.31 | $4.6 | $5.31 | $5.35 | $4.5 | 4,802,569 | 05-07-2024 |
$4.47 | $4.4 | $4.47 | $4.57 | $4.32 | 1,322,967 | 05-06-2024 |
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
16.94%Change Percent:
Summit Therapeutics Inc. Company Name:
SMMT Stock Symbol:
NASDAQ Market:
Publication Entitled: Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial HARMONi-A was Featured in Oral Presentation at ASCO 2024 on May 31, 2024 Conference Call to be Held at 8:00am ET on Monday, June 3, 2024 ...
Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0.46 For Subset of Patients Previously Receiving 3 rd Generation EGFR-TKI: PFS Hazard Ratio of 0.48 5.6% Treatment Discontinua...
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday's session after the company posted mixed first-quarter results. Sentine...